

Biochemistry

KEYWORDS:

Kalazar, LD positive, potassium, Amphotericin B, fever, rigor.

TO EVALUATE SERUM POTASSIUM DURING
AMPHOTERICIN B THERAPY IN VISCERAL
LEISHMANIASIS



Volume - 8, Issue - 4, April - 2023

ISSN (O): 2618-0774 | ISSN (P): 2618-0766

**Dr. Sushant Kumar
Sharma**

Associate Professor department of Surgery, Sri Krishna Medical College, Muzaffarpur

Dr. Anant Prasad*

Associate Professor and HOD, Department of Biochemistry, Sri Krishna Medical College Muzaffarpur*Corresponding Author

INTERNATIONAL JOURNAL
OF PURE MEDICAL RESEARCH



ABSTRACT

OBJECTIVES

The present work is aimed to evaluate potassium level during Amphotericin B therapy is different stages of Kala-azar and to see whether potassium supplementation is required during therapy. Amphotericin B was used for 20 days after on initial base line estimation of potassium. Estimation were done during the treatment and again at follow up.

Material

The material for the present study were selected from MOPD and indoor Medical wards of Sri Krishna Medical College and Hospital Muzaffarpur Bihar from April 2019 to January 2020. A total of forty cases were undertaken for this study. The cases were of both sexes and from all age groups, except those below 10 years.

Methods

The suspected patients presenting with fever including those treated for kala-azar with sodium antimony gluconate were admitted and splenic aspiration was done. Bone marrow aspiration was done only in those cases where spleen was not palpably enlarged.

Only LD positive patients were included in this study. A detailed history of every case was taken then a through clinical examination was performed.

Initial Assessment:

A detail history of every case was taken under the following heading Name, age, sex, religion, Economic status, occupation, full address. Complains of the patients with duration in chronological order.

Types of fever – with/without chills or rigor.

History of Patients illness, history of past illness, family history, personal and social history, Drug history.

Systemic Examination

1. Abdomen, Liver – size consistency margin, tenderness. Spleen – size, consistency, margin, notch surface tenderness. Any other lump in the abdomen.
2. Other systems

Investigation

To establish the diagnosis splenic puncture was done. prior to doing splenic aspiration prothrombin time bleeding time and clotting time were done and the procedure was avoided if these were significantly increased. Size of the spleen and liver were also measured. TLC, DLC, Hb%, Platelet count, blood urea serum creatinine, serum potassium, R/E of urine X-ray chest, ECG, Fundoscopy were also done. Serum potassium was estimated by auto analyzer.

Introduction

Visceral Leishmaniasis has existed in India among the plains of rivers Ganga and Brahmaputra. This disease is mainly distributed in the

eastern sector of country viz West Bengal, Bihar and Assam.

The incidence of Kalazar touched an all time low during 1958-64 mainly due to massive spraying of insecticides for Malaria Eradication. Since then the incidence has been steadily increasing. In the state of Bihar only 250000 cases were reported in DGHS Govt. of India (1992)

Kalazar in India is caused by the Parasite *Leishmania donovani* and transmitted by sandfly and the reservoir in our country is thought to be anthroponotic. Many drugs have been tried for the treatment of Visceral leishmaniasis viz. Antimonials, Pentamidine Amphotericin B, Ketoconazole, Gold salt, Allopurinol, Gabreomycin Gama interferon etc.

Sodium Antimony Gluconate is the treatment of choice. Unfortunately 25% Patients show unresponsiveness to stibogluconate. This can be either primary or secondary. WHO (TDR, December 1996) reported over 10,000 cases of visceral leishmaniasis only in the state of Bihar Pentamidine was used in these cases with great success. Although relapse have been reported that relatively high proportion of Patients with visceral leishmaniasis, failed to respond to Pentamidine in India, Kenya and China. The major disadvantage of Pentamidine is its serious adverse reaction.

The scenario has now shifted to Amphotericin B as the other second line. There are two forms of this drug – one is the conventional Amphotericin B and the other is Amphotericin B Lipid complex

Although Amphotericin B lipid complex is shown to be more effective with less adverse effects, but due to its high cost and non availability, is out of reach of most of the Patients of this country.

So the mainstay of treatment is still Amphotericin B. Amphotericin B has selective toxicity for leishmania. As it probably intercalates with parasite ergosterol precursors of ergosterol in presence to host cholesterol (Burman, 1996). This is a very effective second line drug and has resulted in substantial reduction in treatment failure.

Fever, Chills and phlebitis are few common side effects. Apart from these the major side effect is renal complication, which rarely occur during or after treatment of visceral leishmaniasis, as the renal failure is dose dependent, although permanent damage to renal tubules may occur in short courses.

Permanent functional deficit are uncommon in patients in whom renal function was normal prior to treatment, unless a total dose in excess of 3-4 gm is given to an adult (Goodman Gilman, 1996).

Hypokalaemia occurs during treatment with this drug which is mainly due to renal wasting, and renal tubular acidosis.

About one third of patients on prolonged therapy require

supplementation of potassium (Goodman Gilman 1996), Davidson R.N. (Lancet, 1991). Hypokalaemia is common with conventional Amphotericin B, and toxicities are low with liposomal Amphotericin B. Thakur C.P. (National Med J. India) showed a minor fall in potassium on treatment with Amphotericin B. Thakur C.P. in this report (National Med J. India 1995 vol 8) showed two patients of Kala-azar who developed cardiac arrest after Amphotericin B infusion and both had electrolyte imbalance including Hypokalaemia. He also showed that correction of the imbalance prevented recurrence. Maddex et al observed that Hypokalaemia may develop in patients on Amphotericin B therapy within first two weeks.

Discussion

During study normal level of serum potassium was taken as (3.5-5 mEq/L). During treatment serum potassium estimated and ECG were done at weekly intervals.

Those patients who developed hypokalemia were kept into two groups.

Group I included those patients in whom serum K⁺ level was between 3-3.4 mEq/L and group II patients had serum K⁺ level <3 mEq/L. This was done because only group II patients were given high potassium diet, from the day they became hypokalemic.

This was done on the basis of treatment guideline given in Oxford text book of Medicine 1996, (Vol.3) which wise "in otherwise healthy subject most physicians will treat" those in whom potassium concentration are consistently below 3 mEq/L. Both the groups were closely monitored thereafter in group II patients, who were received potassium rich diet, estimated of potassium level was done on alternate days from the day of hypokalemia to the end of therapy. Patients of group I were not given high potassium diet. At the end of therapy, splenic aspiration for LD bodies was done to establish parasitological cure and all the test were repeated. Patients were followed up and all the test including serum potassium estimation were again done on 60th days.

TREATMENT

Amphotericin B available as 50 mg yellow lyophilized powder vial. The vial were kept in refrigerator until used. 10 ml of sterile water for injection was added to reconstitute the drug so the prepared concentration was 5 mg/ml. The required amount of drugs was added to 500 ml of 5% glucose.

On first day 30 ml of reconstituted drugs was given through intravenous infusion and hypersensitivity reactions were noted. If no reaction occurred the rest of the drug was infused over 2 hrs in a peripheral vein. The drug was given daily and in full dosage from the first day of treatment and adverse reaction if any was noted.

This dose schedule was according to Thakur et al (Ann. Trop. Med. Parasitol 1994, 88: 365-70). The regime was continued for 20 days total dose was 20 mg/kg only weight and was in accordance with Crofts et al (1976) and Thakur C.P (1993).

Fever with shaking chills were treated by stopping infusion for sometimes in mild cases and with paracetamol tablets for more severe cases. After this the infusion was restarted at a very slow rate. Care was taken to avoid the use of steroid injections although they were kept ready for use in emergency since these drugs always causes hypokalemia.

Physical examination:

| | | |
|---------------|-----------------|-------------|
| General built | Anemia | Nutrition |
| Mental Status | Jaundice | Pulse |
| Respiration | Lymphadenopathy | Temperature |
| Weight in kg | Neck Veins. | Cyanosis |
| Clubbing. | Thyroid | |

Results

40 cases of visceral leishmaniasis were taken up for the study. It was observed that maximum number of patients were in 10-20 years age group and minimum in 51-60 years age group. These were 28 males (70%) and 12 females (30%).

The mean level of total leukocyte count, haemoglobin concentration and body weight increased markedly after treatment.

Mean serum potassium level of all the forty patients before treatment and 1st, 2nd and 3rd week and follow up were 4.24±0.40 mEq/L, 4.11±0.40 mEq/L, 4.18±0.37 mEq/L, 4.26±0.38 mEq/L respectively, 15 out of forty patients developed hypokalemia (37.5%), 6 patients become hypokalemic from 1st week (15%). One of these six patients attained normal serum potassium level in 2nd week without potassium supplementation. Rest of the five plus eight more patients become hypokalemic in 2nd week.

The mean level of serum potassium of 15 hypokalemic patients before treatment in 1st, 2nd and 3rd week and follow up were 3.98±0.34, 3.6±0.29, 3.08±0.34, 3.86±0.20 and 4.12±0.30 mmol/L respectively.

Hypokalemic patients were divided into two groups. Group II patients (serum K⁺ <3 mEq/L) were monitored on alternate days and were given potassium rich diet. Group I patients (serum K⁺ 3-3.4 mEq/L) were not given high potassium diet. Level of serum potassium came to normal in both the groups at the end of therapy and remained normal at follow up.

Over all six patients showed ECG changes of hypokalemia. No significant change like heart block or arrhythmia were seen. ECG change did not correlate well with level of hypokalemia and become normal at the end of therapy.

The change in serum potassium level on the day was not significant (p>0.05) but on 14 day became significant (p<0.01). Thereafter at the end of therapy and follow up the level was not significant.

CONCLUSION

Therapy with Amphotericin-B caused mild to moderate hypokalemia mainly during first two weeks and the overall incidence was 37.5%. Supplementation of Potassium was not necessary for all hypokalemic patients. Only 20% patients in whom Serum K⁺ level went below 3 mEq/L, were given potassium rich diet. This was sufficient to correct hypokalemia.

In subsequent check up i.e. at the end of treatment and at follow up the potassium levels of all the forty patients were within normal limits.

So keeping in mind the enormous burden of kala-azar patients both due to ongoing endemicity and epidemic, blind potassium therapy in all patients being treated with Amphotericin B is not required.

REFERENCES

1. Current Medical Diagnosis and Treatment 43 Edition 2004.
2. Thakur, C.P, 1995, correlation of serum electrolyte prevents cardiac arrhythmias during Amphotericin B administration. Nat. Med. J India 8:13-14.
3. Davidson, R.N., et al, 2013 "Liposomal Amphotericin B in drug resistant Visceral Leshmaniasis" LANCET, 337, PP 1061-1062.
4. Davidson's Principles and practice of Medicine 1995, 17th ed., PP 156-157.
5. Goodman Gilman's The Pharmacological basis of Therapeutics, 2006 Chapter 49.
6. MSF, Holland Study in Southern Sudan Manuscript unpublished from study report 2013, Ambisome in Visceral Leshmaniasis Davidson, R.N.
7. Napier, L.E., 2006, An epidemiological consideration of transmission of kala-azar in India, Indian J. Med-Res, 14; 219-265.
8. Napier L.E. 1946, Principles and Practice of Tropical, Med, Mc Millan, New York, Oxford Textbook of Medicine, Third Edition, 2010. Vol 3.
9. Park, K., 1994, Park's textbook of Preventive and social Medicine, 14th ed, 215.
10. WHO. 2010 Proceeding of WHO on Leshmaniasis WHO, 2010, Report of the expert committee. The Leshmaniasis WHO Tech. Rep, Ser. 701:104.